Apr 14, 2010 by Brian Orelli, PhDOops, This Drug Works Too WellInterMune's candidate is very efficient, but a lower dose might bring fewer side effects.
Apr 13, 2010 by Brian Orelli, PhDTeva Gets Less GenericThe generic-drug maker makes a major push into branded-drug development.
Apr 12, 2010 by Brian Orelli, PhDPay for Our Drugs or ElseIs the pharmaceutical industry's muscle strong enough?
Apr 9, 2010 by Brian Orelli, PhDDouble Your Biotech Returns! Really!Taking a closer look at leveraged biotech ETFs.
Apr 9, 2010 by Brian Orelli, PhDIs Boston Scientific Turning It Around?Selling off a pair of units could help.
Apr 8, 2010 by Brian Orelli, PhDIs Icahn Stuck in the Station?Saving Genzyme's train wreck may be difficult.
Apr 7, 2010 by Brian Orelli, PhDWeekly Walk of Shame: Pfizer Cheats, and WinsToo big to fail strikes the pharmaceutical industry.
Apr 7, 2010 by Brian Orelli, PhDTeva: Hold Until Things Turn UglyDespite the drugmaker's recent success, its future looks precarious.
Apr 7, 2010 by Brian Orelli, PhDMonsanto Grows in a Different DirectionUnfortunately, not fast enough.
Apr 6, 2010 by Brian Orelli, PhDKill It! Double-Teaming MalariaMalaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome.
Apr 5, 2010 by Brian Orelli, PhDUp 30%? What Are You People On?Fast-track designations aren't worth much more than the paper they're printed on.
Mar 31, 2010 by Brian Orelli, PhDIs Pfizer a Buy?Pfizer seems most appropriate for a certain type of investor.
Mar 31, 2010 by Brian Orelli, PhDHow Do You Put a Price on Pain?Price controls could wreak havoc on expensive therapies that control pain.
Mar 31, 2010 by Brian Orelli, PhDWhen One Patent Means So MuchThe loss of patents on genes could have far-reaching consequences.
Mar 31, 2010 by Brian Orelli, PhDA Double-Digit Jump? For That?Isis' drug discovery license doesn't look too exciting to me.
Mar 30, 2010 by Brian Orelli, PhDInvest in This Space at Your Own RiskLung cancer is a tough foe for drugmakers.
Mar 30, 2010 by Brian Orelli, PhDFDA Lags, Investors FleeDespite having a SPA, Cephalon gets no love from the FDA.
